← Back to Clinical Trials
Recruiting NCT07342920

NCT07342920 Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07342920
Status Recruiting
Phase
Sponsor University Hospital, Strasbourg, France
Condition Cystic Fibrosis
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-10-15
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-10-15 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Eligibility Criteria

Inclusion Criteria: * Adult patient (≥ 18 years old) * With confirmed cystic fibrosis * Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center Exclusion Criteria: * Patients who have undergone a double lung transplant for cystic fibrosis.

Contact & Investigator

Central Contact

Romain Kessler, MD, PhD

✉ Romain.Kessler@chru-strasbourg.fr

📞 33 3 69 55 03 77

Frequently Asked Questions

Who can join the NCT07342920 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cystic Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07342920 currently recruiting?

Yes, NCT07342920 is actively recruiting participants. Contact the research team at Romain.Kessler@chru-strasbourg.fr for enrollment information.

Where is the NCT07342920 trial being conducted?

This trial is being conducted at Strasbourg, France.

Who is sponsoring the NCT07342920 clinical trial?

NCT07342920 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology